David Matthew Friedman - 26 May 2026 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Reporting relationship: Director
Issuer ticker: BNTC
Reported as of: 26 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2026, 21:10:14 UTC
Prior SEC filing: 28 May 2026
Source filing: View source filing
Reporting owner signature: /s/ David Matthew Friedman

Key filing fact

David Matthew Friedman filed Form 4 for Benitec Biopharma Inc. (BNTC) on 28 May 2026.

Key facts

This page summarizes David Matthew Friedman's Form 4 filing for Benitec Biopharma Inc. (BNTC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 May 2026, 21:10.

Change

Previous filing in this sequence was filed on 28 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002108980 Primary reporting owner

Friedman David Matthew

Relationship: Director
Address: 540 MADISON AVENUE, 7TH FLOOR, NEW YORK
Signature: /s/ David Matthew Friedman
Signature date: 28 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BNTC transaction Derivative

Options (right to buy)

Award

Transaction value
Shares: +35,000
Change %
Price: $0.000000^*
Shares after: 35,000
Date: 26 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $11.45
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Friedman in connection with his role as a member of the Issuer's Board of Directors. Mr. Friedman, as a Managing Director of Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds"), is holding such options for the benefit of the Funds, and as such Mr. Friedman disclaims beneficial ownership of such options. The Funds, and Suvretta Capital, the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Friedman's board service.

Footnote F2

The Options will vest in full on the earlier of immediately prior to the Issuer's next annual meeting of stockholders and May 26, 2027.